复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

已收盘 10-20 16:08:20

17.080

-0.030

-0.18%

最高17.320	最低16.860	成交量168.55万
今开17.220	昨收17.110	日振幅2.69%
总市值452.28亿	流通市值90.52亿	总股本26.48亿
成交额2,883万	换手率0.32%	流通股本5.30亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":17.08,"timestamp":1792483700003,"preClose":17.11,"halted":0,"volume":1685500,"delay":0,"changeRate":-0.001753360607831744,"floatShares":530000000,"shares":2648000000,"eps":1.4928335975638467,"marketStatus":"已收盘","change":-0.03,"latestTime":"10-20 16:08:20","open":17.22,"high":17.32,"low":16.86,"amount":28828727,"amplitude":0.026885,"askPrice":17.09,"askSize":10500,"bidPrice":17.08,"bidSize":125500,"shortable":3,"etf":0,"ttmEps":1.5045975964964602,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792546200000},"marketStatusCode":5,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":17.11,"dividendRate":0.026763,"openAndCloseTimeList":[[1792459800000,1792468800000],[1792472400000,1792483200000]],"volumeRatio":0.707243,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":23.14,"timestamp":1792479600000,"preClose":22.93,"halted":0,"volume":11948000,"delay":0,"premium":"-37.21"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2676669466","title":"贝莱德在复星医药的H股好仓比例上升0.29%至6.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676669466","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676669466?lang=zh_cn&edition=full","pubTime":"2026-10-20 17:21","pubTimestamp":1792488060,"startTime":"0","endTime":"0","summary":"南财智讯10月20日电，香港交易所披露信息显示，BlackRock,Inc.（贝莱德）在复星医药的H股好仓（L）比例于10月14日从5.99%上升至6.28%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610203901385187.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610203901385187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02196","BK0175","BK0188","BK1191","BK0196","BK0028","BK0060","BK0239","BK0096","BK1515","BK1593","BK0183","BK0012","600196","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676666035","title":"复星医药：公司坚持对资金、负债及其风险的管控","url":"https://stock-news.laohu8.com/highlight/detail?id=2676666035","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676666035?lang=zh_cn&edition=full","pubTime":"2026-10-20 17:09","pubTimestamp":1792487356,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药10月20日在投资者关系平台上答复投资者关心的问题。截至目前，公司存量担保均发生于公司与控股子公司之间、或控股子公司之间，担保所涉融资系为满足相关控股子公司实际经营之需要，风险相对可控。公司坚持对资金、负债及其风险的管控，近年来持续优化融资结构、控制融资成本，并审慎开展担保，以期保持合理负债水平，持续推动公司稳健经营和可持续发展。感谢您对公司的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000025560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","600196","BK0012","BK0188","BK1191","BK1593","BK0096","BK1515","BK0028","BK0183","BK0175","BK0239","BK0060","BK0187","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676660396","title":"复星医药：公司自身将持续聚焦创新药放量、药械新品上市、海外业务拓展及经营效率提升等重点工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2676660396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676660396?lang=zh_cn&edition=full","pubTime":"2026-10-20 17:09","pubTimestamp":1792487355,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药10月20日在投资者关系平台上答复投资者关心的问题。二级市场股价短期分时波动受市场整体环境、投资者交易行为、资金流向及市场情绪等多重因素影响，具有较强的市场交易属性。公司业务覆盖制药、医疗器械与医学诊断、医疗健康服务等领域。公司自身将持续聚焦创新药放量、药械新品上市、海外业务拓展及经营效率提升等重点工作，以持续改善经营表现，为公司长期价值提供支撑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000025558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0012","600196","159992","BK0239","02196","BK0028","BK1515","BK1574","BK0188","BK1593","BK1161","BK1191","BK0060","BK0196","BK0096","BK0187","BK0183","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675789518","title":"复星医药（600196）披露为控股子公司提供担保的进展公告，10月16日股价下跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675789518","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675789518?lang=zh_cn&edition=full","pubTime":"2026-10-16 22:53","pubTimestamp":1792162390,"startTime":"0","endTime":"0","summary":"近日，上海复星医药（集团）股份有限公司发布《关于为控股子公司提供担保的进展公告》。公告显示，公司为多家控股子公司提供担保，涉及复星健康、复星雅立峰、健嘉东麟、蚌埠健嘉、武汉健嘉、成都健嘉和北京健嘉，担保金额合计人民币48,257.32万元。截至2026年10月16日，本集团实际对外担保余额折合人民币约1,831,534万元，占2025年末经审计净资产的37.58%，无逾期担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600040852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","BK0187","02196","BK0188","BK0012","BK0028","BK0239","BK1191","BK0060","BK1515","BK1593","BK0183","BK0096","BK0175","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178551425","title":"复星医药(02196)新增对七家控股子公司4.93亿元担保 累计担保占净资产37.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178551425","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178551425?lang=zh_cn&edition=full","pubTime":"2026-10-16 18:31","pubTimestamp":1792146712,"startTime":"0","endTime":"0","summary":"2026年10月16日，复星医药发布《关于为控股子公司提供担保的进展公告》，披露公司及下属企业近日与金融机构签署多份保证合同，合计新增担保金额4.93亿元，全部在已获股东会批准的担保额度内，无需再次提交董事会或股东大会审议。公告显示，截至2026年10月16日，包括本次担保在内，复星医药集团对外实际担保余额为183.1534亿元，占公司2025年12月31日经审计归属于上市公司股东净资产的37.58%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674580571","title":"复星医药（600196）披露第三季度业绩审议安排，10月12日股价下跌0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674580571","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674580571?lang=zh_cn&edition=full","pubTime":"2026-10-12 22:53","pubTimestamp":1791816795,"startTime":"0","endTime":"0","summary":"截至2026年10月12日收盘，复星医药报收于23.66元，较前一交易日下跌0.96%，最新总市值为631.82亿元。该股当日开盘23.93元，最高24.1元，最低23.62元，成交额达4.24亿元，换手率为0.84%。近日，复星医药发布H股公告，披露公司董事会谨定于2026年10月27日举行会议，考虑及通过本公司及其附属公司截至2026年9月30日止九个月的第三季度业绩并予以刊发。公告日期为2026年10月12日，并列出了当前董事会成员名单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200035791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","BK0175","BK0096","02196","BK1515","BK1191","BK0183","BK0012","BK1593","BK0060","BK0188","BK0028","BK0196","BK0187","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104855310","title":"复星医药（02196）公告：董事会将于10月27日审议2026年前三季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1104855310","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104855310?lang=zh_cn&edition=full","pubTime":"2026-10-12 16:42","pubTimestamp":1791794541,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司（02196）10月12日公告称，公司董事会拟于2026年10月27日（星期二）召开会议，主要议程包括审议并通过公司及其附属公司截至2026年9月30日止九个月的第三季度业绩，并对外发布相关业绩报告。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674301830","title":"贝莱德在复星医药的H股好仓比例上升0.38%至6.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674301830","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674301830?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:18","pubTimestamp":1791537480,"startTime":"0","endTime":"0","summary":"南财智讯10月9日电，香港交易所披露信息显示，BlackRock,Inc.（贝莱德）在复星医药的H股好仓（L）比例于10月6日从5.68%上升至6.06%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610093891326921.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610093891326921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK1593","BK0096","BK0012","BK1515","BK0239","BK1191","BK0183","BK0187","BK0196","600196","BK0060","BK0028","BK0175","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673701286","title":"股市必读：复星医药新发布《复星医药关于高级管理人员辞任的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673701286","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673701286?lang=zh_cn&edition=full","pubTime":"2026-10-08 01:48","pubTimestamp":1791395294,"startTime":"0","endTime":"0","summary":"公司公告汇总：截至9月30日，复星医药H股已发行股份减少11,077,000股，系公司当月多次以每股16.21至18.16港元价格购回所致。公司公告汇总复星医药关于高级管理人员辞任的公告2026年9月30日，Wenjie Zhang先生因个人原因辞去复星医药联席总裁职务，辞任自送达董事会时生效；其原定任期至2028年6月23日；辞任后不再担任上市公司及其控股子公司任何职务；不存在未履行完毕的公开承诺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800000997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0096","BK1515","BK0012","BK0188","BK0239","BK0183","BK0060","02196","600196","BK1191","BK1593","BK0196","BK0175","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177085102","title":"复星医药：贝莱德减持，好仓比例降至5.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177085102","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177085102?lang=zh_cn&edition=full","pubTime":"2026-10-02 17:27","pubTimestamp":1790933226,"startTime":"0","endTime":"0","summary":"贝莱德于2026年9月28日以非现金资产为代价场外减持复星医药（02196）H股142.43万股，涉及原因系不再持有该股份的保证权益。属场外交易（代价性质：非现金资产），未经联交所公开市场撮合，不属二级市场直接买卖。贝莱德此次减持前持有复星医药好仓3334.34万股，占比6.04%；减持后持股量为3191.91万股，好仓比例降至5.78%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671889817","title":"复星医药（600196）披露高级管理人员辞任公告，9月30日股价上涨2.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671889817","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671889817?lang=zh_cn&edition=full","pubTime":"2026-09-30 22:15","pubTimestamp":1790777726,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘，复星医药报收于24.02元，较前一交易日上涨2.69%，最新总市值为641.44亿元。近日，复星医药发布《关于高级管理人员辞任的公告》。公告显示，2026年9月30日，上海复星医药（集团）股份有限公司董事会收到Wenjie Zhang先生的书面辞职函。因个人原因，Wenjie Zhang先生辞去公司联席总裁职务，辞任自送达董事会时生效。其原定任期至2028年6月23日。Wenjie Zhang先生不再担任上市公司及其控股子公司任何职务，且不存在未履行完毕的公开承诺。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000037960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1515","BK1191","BK1593","600196","02196","BK0028","BK0096","BK0060","BK0175","BK0196","BK0188","BK0187","BK0012","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178666788","title":"复星医药（02196）发布公告：联席总裁Wenjie Zhang辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=1178666788","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178666788?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:52","pubTimestamp":1790761936,"startTime":"0","endTime":"0","summary":"2026年9月30日，复星医药（02196）公告称，公司董事会当日收到联席总裁Wenjie Zhang先生的书面辞职函。Wenjie Zhang因个人原因辞去联席总裁职务，辞任自函件送达董事会时生效。\n公告显示，Wenjie Zhang原任期本应于2028年6月23日届满。辞任后，Wenjie Zhang将不再在上市公司及其控股子公司任职，且不存在未履行完毕的公开承诺。\n公司董事会对Wenjie Zhang先生在任职期间所做的工作表示感谢，并已按照相关程序完成交接。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671208351","title":"复星医药(02196)：Wenjie Zhang辞任联席总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2671208351","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671208351?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:51","pubTimestamp":1790761912,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，2026年9月30日，公司董事会收到 Wenjie Zhang 先生的书面辞职函。因个人原因，Wenjie Zhang 先生向董事会辞去公司联席总裁职务，其辞任于送达董事会时生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02196","BK0188","BK1191","BK0012","BK0096","BK1593","BK0183","BK1515","BK0196","BK0060","BK0187","BK0239","BK0175","BK0028","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159717002","title":"复星医药：贝莱德增持，好仓比例升至6.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159717002","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159717002?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:30","pubTimestamp":1790760610,"startTime":"0","endTime":"0","summary":"贝莱德于2026年9月25日以非现金资产代价取得复星医药H股148.41万股股份（属取得股份保证权益的方式增持），该笔为场外交易（代价性质：非现金资产），未经联交所公开市场撮合，不属二级市场直接买卖。贝莱德此次增持前持有复星医药好仓3196.34万股，占比5.79%；增持后持股量为3344.74万股，好仓比例升至6.06%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183093657","title":"复星医药更新2026年9月股份变动月报：回购H股1107.70万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1183093657","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183093657?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:27","pubTimestamp":1790756831,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司于2026年9月30日披露了截至2026年9月30日止的股份变动月报表。根据公告，本月底公司H股及A股在已发行股份总数上保持稳定，但当月进行了多次H股回购操作。复星医药本月H股的法定股本数量仍为551,940,500股，与上月底持平。公告披露，复星医药于2026年9月1日至2026年9月25日期间先后进行14次H股回购，涉及回购股份总数合计11,077,000股，成交价格区间为每股16.21港元至18.16港元，均被纳入公司库藏股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671224954","title":"股市必读：复星医药新发布《复星医药关于2025年A股股票期权激励计划预留授予结果公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2671224954","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671224954?lang=zh_cn&edition=full","pubTime":"2026-09-30 01:16","pubTimestamp":1790702172,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘，复星医药报收于23.39元，上涨0.65%，换手率1.37%，成交量29.06万手，成交额6.85亿元。公司公告汇总复星医药关于2025年A股股票期权激励计划预留授予结果公告上海复星医药（集团）股份有限公司已完成2025年A股股票期权激励计划的预留授予登记工作。本次预留授予登记日为2026年9月24日，实际授予A股期权合计723,300份，涉及激励对象共99人，行权价格为27.93元/股，股票来源为公司从二级市场回购的A股库存股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000001772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["82822","02823","07233","BK1147","02843","BK1593","BK0012","03130","02846","BK0028","BK0239","82823","BK0060","03188","600196","BK1515","BK0187","BK0188","159982","82843","BK0175","BK0196","02827","82846","83188","BK0096","BK0183","02822","83130","399300","BK1191","02196","BK1610"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671251705","title":"股市必读：复星医药新发布《复星医药H股公告-翌日披露报表》","url":"https://stock-news.laohu8.com/highlight/detail?id=2671251705","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671251705?lang=zh_cn&edition=full","pubTime":"2026-09-29 01:12","pubTimestamp":1790615537,"startTime":"0","endTime":"0","summary":"公司公告汇总复星医药H股公告-翌日披露报表上海复星医药(集团)股份有限公司于2026年9月25日购回62,000股H股股份，每股购回价介乎17.34港元至17.47港元，总代价为1,080,535港元。该等股份拟持作库存股份。本次购回在联交所进行，占购回前已发行股份的0.01%。复星医药关于2025年A股股票期权激励计划预留授予结果公告上海复星医药（集团）股份有限公司已完成2025年A股股票期权激励计划的预留授予登记工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900001550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1593","BK1515","BK1191","BK0175","BK0188","02196","BK0183","BK0028","BK0012","BK0196","BK0060","BK0239","BK0187","600196","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133323834","title":"复星医药公布2025年A股期权激励计划预留授予结果 共计授予72.33万份期权","url":"https://stock-news.laohu8.com/highlight/detail?id=1133323834","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133323834?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:21","pubTimestamp":1790587292,"startTime":"0","endTime":"0","summary":"公司已完成2025年A股股票期权激励计划的预留授予及登记工作。本次实际向99名激励对象授予A股期权合计723,300份，授予日为2026年8月28日，行权价为人民币27.93元/股，股票来源为公司已/将从二级市场回购的A股库存股份。期权代码为1000001131和1000001132。第二个行权期为自预留授予日起满24个月后的首个交易日至36个月的最后一个交易日，可行权数量占50%。复星医药表示，未满足行权条件或在行权期内未行权的期权将被注销。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670240219","title":"复星医药于9月25日斥资108.05万港元回购6.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670240219","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670240219?lang=zh_cn&edition=full","pubTime":"2026-09-28 08:27","pubTimestamp":1790555220,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端复星医药（02196）发布公告，于2026年9月25日，该公司斥资108.05万港元回购6.2万股。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-09-28/doc-initirzp9728819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK0239","BK0060","BK0175","BK0196","BK0012","02196","BK0096","BK0028","BK0187","BK0188","BK1593","BK0183","BK1515","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670381409","title":"股市必读：复星医药新发布《复星医药关于控股子公司签订合作与许可协议的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670381409","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670381409?lang=zh_cn&edition=full","pubTime":"2026-09-28 01:12","pubTimestamp":1790529134,"startTime":"0","endTime":"0","summary":"公司公告汇总：复星医药于9月24日及25日连续两日实施H股回购，合计购回134,000股，总代价约235万港元，均拟作库存股份。公司公告汇总复星医药关于控股子公司签订合作与许可协议的公告2026年9月23日，复星医药控股子公司复宏汉霖与Amberstone签订《合作与许可协议》，获得基于T-MATE技术平台针对两个靶点开发两款T细胞衔接器产品的全球独家许可。本次购回在联交所进行，占购回前已发行股份的0.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800000761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02196","BK0012","BK1191","BK0096","BK0187","600196","BK1515","BK1593","BK0239","BK0196","BK0028","BK0060","BK0183","BK0188","BK0175"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0425},{"period":"1month","weight":-0.0018},{"period":"3month","weight":0.0549},{"period":"6month","weight":-0.1282},{"period":"1year","weight":-0.2744},{"period":"ytd","weight":-0.101}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司通过五个分部开展业务。制药分部主要从事药品的研发、生产和销售。医疗器械与医学诊断分部主要从事医疗器械和诊断产品的研发、生产和销售。医疗健康服务分部主要从事提供医疗健康服务及医院管理。医药分销和零售分部主要从事医药、器械分销和零售。 该公司还运营其他分部。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044495},{"month":2,"riseRate":0.714286,"avgChangeRate":0.036179},{"month":3,"riseRate":0.571429,"avgChangeRate":0.044259},{"month":4,"riseRate":0.357143,"avgChangeRate":0.026},{"month":5,"riseRate":0.428571,"avgChangeRate":0.024935},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.032656},{"month":7,"riseRate":0.642857,"avgChangeRate":0.03393},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.040558},{"month":9,"riseRate":0.5,"avgChangeRate":0.021862},{"month":10,"riseRate":0.428571,"avgChangeRate":0.013651},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034477},{"month":12,"riseRate":0.428571,"avgChangeRate":0.015129}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}